Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.
Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.
An experimental hemophilia A therapy from Sanofi and partner Sobi has met the goals of a pivotal study, and the pharmaceutical giant is now planning global regulatory submissions for later this year. The drug could compete against a blockbuster hemophilia A treatment marketed by Roche.
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
The Swedish drugmaker acquired rights to the drug from Switzerland-based Novimmune in July for about $50 million, plus about $400 million in payments over eight years.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.